JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Nalidixic acid resistance in Salmonella strains with decreased susceptibility to ciprofloxacin isolated from humans in Turkey.

The aim of this study was to evaluate the value of nalidixic acid resistance as an indicator of decreased susceptibility to ciprofloxacin (MIC = 0.125 - 1 mg/L) in Salmonella isolates from humans (n = 620) in Turkey. One isolate was found to be resistant, and the remaining isolates were susceptible to ciprofloxacin with the Clinical and Laboratory Standards Institute breakpoints; however, 75 isolates (12.1%) had decreased susceptibility. Resistance to nalidixic acid was observed in 76 (12.3%) isolates in the disk diffusion test. Seventy-four of these isolates had decreased susceptibility, one was fully resistant, and one isolate was susceptible to ciprofloxacin. One isolate with decreased susceptibility to ciprofloxacin was intermediate to nalidixic acid. Screening with 30-microg nalidixic acid disks had a sensitivity of 98.6% and a specificity of 99.8% for determination of decreased susceptibility to ciprofloxacin.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app